TORONTO, September 24, 2018 − 3D Signatures Inc. (TSX-V:DXD) (the “Company” or “3DS“) is pleased to announce that further to the Company’s May 31, 2018 and September 17, 2018 news releases, the Company’s shares will resume trading at the open on Wednesday, September 26, 2018. 

The Company acknowledges that the current Board and Audit Committee do not currently meet the independence requirements set by the TSX-V. The Company is working to remedy these deficiencies as soon as possible. 

“I am extremely pleased to see 3D Signatures return to trading and now focus on validation of its technology. Shareholder value and patient outcomes are the Company’s priorities. Dr. Mai’s work over the past 20 years must be validated and commercially developed, particularly in the field of Alzheimer’s disease, where there is no reliable diagnostic tool. This is an enormous commercial market with limited competition,” Hugh Rogers, Interim Chair. 

About 3DS 

3DS (TSX-V:DXD) is a personalized medicine company with a proprietary software platform, TeloViewTM, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the three-dimensional analysis of telomeres, the protective caps at the ends of chromosomes. 3DS’ TeloViewTM software platform measures the organization of the genome and its correspondence to; the stage of a given disease, the rate of progression of the disease, how different diseases will respond to various therapies, and a drug’s efficacy and toxicity. 3DS’ proprietary imaging software is designed to go beyond identifying whether a patient suffers from a specific disease or condition. Instead, the TeloViewTM platform is designed to inform clinicians and patients with respect to how to personalize treatment and best manage an individual’s disease based on their unique TeloViewScoreTM. As healthcare moves increasingly toward better informed, patient-centric approaches, the Company intends for the TeloViewTM platform to deliver personalized medicine that allows for better treatments, leading to better outcomes. 

The TeloViewTM platform is supported by 25 clinical studies involving more than 3,000 patients and 20 different cancers, plus Alzheimer’s disease. 3DS benefits from twenty years of research, $25M of non-dilutive investment into its platform and more than 130 supporting publications, and holds a portfolio of patents related to three-dimensional telomere analysis for proliferative diseases, including (but not limited to) hematological disorders such as Hodgkin’s lymphoma, multiple myeloma, and chronic myeloid leukemia. 3DS’ intellectual property portfolio also covers prostate cancer, breast cancer, lung cancer, melanoma, colorectal cancer, and Alzheimer disease. 

For more information, visit the Company’s website at: 

For further information, please contact: 

Hugh Rogers 

Interim Chair 


MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7 


MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto ON, M5G 1L7 TSX.V: DXD 

TSX Venture Exchange Disclaimer 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

Cautionary Note Regarding Forward-Looking Statements 

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding access to funding, commercial opportunities, the Company’s assessment of current clinical programs, and efficacy and success of the TeloViewTM platform are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.